Use of gene networks from full genome microarray libraries to identify functionally relevant drug-affected genes and gene regulation cascadesSAVOIE, Christopher J; ABURATANI, Sachiyo; WATANABE, Shouji et al.DNA research. 2003, Vol 10, Num 1, pp 19-25, issn 1340-2838, 7 p.Article

Crystallizing new approaches for antimicrobial drug discoverySCHMID, Molly B.Biochemical pharmacology. 2006, Vol 71, Num 7, pp 1048-1056, issn 0006-2952, 9 p.Article

The Discovery of Medicines from Plants: A Current Biological PerspectiveMILLER, James S.Economic botany. 2011, Vol 65, Num 4, pp 396-407, issn 0013-0001, 12 p.Article

Target-based drug discovery, genetic diseases, and biologiesHURKO, Orest.Neurochemistry international. 2012, Vol 61, Num 6, pp 892-898, issn 0197-0186, 7 p.Article

Literature mining in support of drug discoveryAGARWAL, Pankaj; SEARLS, David B.Briefings in bioinformatics. 2008, Vol 9, Num 6, pp 479-492, issn 1467-5463, 14 p.Article

Tuberculosis: The drug development pipeline at a glanceVILLEMAGNEA, Baptiste; CRAUSTEA, Celine; FLIPOA, Marion et al.European journal of medicinal chemistry. 2012, Vol 51, pp 1-16, issn 0223-5234, 16 p.Article

Is chemical synthetic accessibility computationally predictable for drug and lead-like molecules? A comparative assessment between medicinal and computational chemistsBONNET, Pascal.European journal of medicinal chemistry. 2012, Vol 54, pp 679-689, issn 0223-5234, 11 p.Article

Genomic approaches to small molecule discoverySTEGMAIER, K.Leukemia. 2009, Vol 23, Num 7, pp 1226-1235, issn 0887-6924, 10 p.Article

Synthesis of (3R, 4S)-3,4,5-trihydroxy-4-methylpentylphosphonic acid as a potential inhibitor of the nonmevalonate pathwayYOSHIOKA, Toshiaki; SHIMIZU, Hiroki; OHRUI, Hiroshi et al.Bioscience, biotechnology, and biochemistry. 2004, Vol 68, Num 6, pp 1259-1264, issn 0916-8451, 6 p.Article

Discovery of Novel Drugs for Promising TargetsMARTELL, Robert E; BROOKS, David G; YAN WANG et al.Clinical therapeutics. 2013, Vol 35, Num 9, pp 1271-1281, issn 0149-2918, 11 p.Article

Discovery of veterinary antiparasitic agents in the 21st Century: A view from industryWOODS, Debra J; KNAUER, Christopher S.International journal for parasitology. 2010, Vol 40, Num 10, pp 1177-1181, issn 0020-7519, 5 p.Conference Paper

Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug designLI DI; KEEFER, Christopher; OBACH, R. Scott et al.European journal of medicinal chemistry. 2012, Vol 57, pp 441-448, issn 0223-5234, 8 p.Article

Evaluation of online extraction/mass spectrometry for in vivo cassette analysisSADAGOPAN, Nalini; PABST, Brandon; COHEN, Lucinda et al.Journal of chromatography. B. 2005, Vol 820, Num 1, pp 59-67, issn 1570-0232, 9 p.Article

Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agentsLUKASIK, Pawel M; ELABAR, Sherifa; LAM, Frankie et al.European journal of medicinal chemistry. 2012, Vol 57, pp 311-322, issn 0223-5234, 12 p.Article

Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegenerationBRUNNER, Dani; BALCI, Fuat; LUDVIG, Elliot A et al.Behavioural processes. 2012, Vol 89, Num 2, pp 187-195, issn 0376-6357, 9 p.Article

Hydrosoluble formazan XTT: its application to natural products drug discovery for LeishmaniaWILLIAMS, Cornelly; ESPINOSA, Omar A; MONTENEGRO, Hector et al.Journal of microbiological methods. 2003, Vol 55, Num 3, pp 813-816, issn 0167-7012, 4 p.Article

2-Arylindoles: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharma-cological ActivityLAL, S; SNAPE, T. J.Current medicinal chemistry. 2012, Vol 19, Num 28, pp 4828-4837, issn 0929-8673, 10 p.Article

Data mining the human gut microbiota for therapeutic targetsCOLLISON, Matthew; HIRT, Robert P; WIPAT, Anil et al.Briefings in bioinformatics. 2012, Vol 13, Num 6, pp 751-768, issn 1467-5463, 18 p.Article

Applications of mass spectrometry in early stages of target based drug discoveryGEJING DENG; SANYAL, Gautam.Journal of pharmaceutical and biomedical analysis. 2006, Vol 40, Num 3, pp 528-538, issn 0731-7085, 11 p.Article

Antimalarial activities of gedunin and 7-methoxygedunin and synergistic activity with dillapiolOMAR, S; GODARD, K; POVEDA, L et al.Annals of applied biology. 2003, Vol 143, Num 2, pp 135-141, issn 0003-4746, 7 p.Article

Protocol for Rational Design of Covalently Interacting InhibitorsSCHMIDT, Thomas C; WELKER, Armin; RIEGER, Max et al.ChemPhysChem (Print). 2014, Vol 15, Num 15, pp 3226-3235, issn 1439-4235, 10 p.Article

Cyclotides, a Novel Ultrastable Polypeptide Scaffold for Drug Discovery : Novel-Peptide-Based Scaffolds for Drug DiscoveryGOULD, Andrew; YANBIN JI; ABOYE, Teshome L et al.Current pharmaceutical design (Print). 2011, Vol 17, Num 38, pp 4294-4307, issn 1381-6128, 14 p.Article

Novel Insights into Biased Agonism at G Protein-Coupled Receptors and their Potential for Drug DesignMARTI-SOLANO, Maria; GUIXA-GONZALEZ, Ramon; SANZ, Ferran et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 28, pp 5156-5166, issn 1381-6128, 11 p.Article

Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486DOLAN, Bridget M; DURON, Sergio G; CAMPBELL, David A et al.Proceedings of the National Academy of Sciences of the United States of America. 2013, Vol 110, Num 14, pp 5671-5676, issn 0027-8424, 6 p.Article

Cellular Reprogramming: A New Technology Frontier in Pharmaceutical ResearchBROCK, Amy; HUI-TONG GOH; BINXIA YANG et al.Pharmaceutical research. 2012, Vol 29, Num 1, pp 35-52, issn 0724-8741, 18 p.Article